Weekender: FDA, aiming to curb another COVID-19 surge, clears Pfizer, Moderna boosters for all adults

Signup | Forward Weekender Nov.​ 20,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — IQVIA Drive productivity and brand performance Address local HCP access restrictions with IQVIA's dynamically deployed sales teams. Learn more.   FDA, aiming to curb another COVID-19 surge, clears Pfizer, Moderna boosters for all adults Soon after the FDA's authorization, a panel of CDC advisers followed with similar recommendations for third doses in adults over 18 years old.  Al Sandrock, Biogen's top scientist and Aduhelm defender, to retire in surprise exit Sandrock championed the controversial Alzheimer's drug, and was integral to the development of several other of Biogen's most important medicines during his 24 years at the biotech.  A startup emerges with $125M and plans to edit the epigenome Chroma Medicine's launch is the latest step in a decadeslong quest by drugmakers to capitalize on research into epigenetics, a way of controlling gene expression without altering DNA. Sponsored Content by WCG IRB Decentralized Clinical Trials: Best practices in moving toward a patient-centric research model Decentralized or virtual clinical trials are focused on bringing the clinical study directly to the participant, offering potential advantages in bringing trial data closer to real-world experience. Download whitepaper. European drugs regulator signals rejection likely for Biogen's Aduhelm A European Medicines Agency panel tasked with reviewing drugs voted against the biotech's controversial Alzheimer's medicine, signaling an approval is unlikely next month. Novo to acquire Dicerna for more than $3B amid RNA drug resurgence The acquisition would give Novo Nordisk ownership of one of the oldest and largest developers of RNA interference drugs, along with a web of potential royalty streams.  Anticipating Aduhelm's costs, Medicare plans big jump in premiums While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket. Recommended For You Improve your recommendations: click here to update your profile. Deep Dive Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy Luxturna, approved four years ago as the first gene therapy for an inherited disease in the U.S., is improving sight and quality of life for several of the patients who received it. BROUGHT TO YOU BY — Galen What makes an acquisition the right fit for both companies? In their latest case study, find out what elements came together to drive success following Galen's acquisition of POA Pharma and what the future holds. Click here to download instantly. From Our Library Webinar - on demand Emerging Pharma: Why Digital Platforms Level the Field ZS Infographic 3 Reasons to Run More ADME Testing During Preclinical Research Xenotech Playbook How BioPharma Leaders Are Increasing ROI Neustar Webinar - on demand Important ADME & Drug-Drug Interaction Considerations for Successful Drug Development Xenotech Webinar - on demand The Future of Biopharmaceutical Quality: A Focus on People, Process, and Proactive Risk Mitigation Samsung Biologics View all resources Best of What We're Reading The Hill CBO: Democrats' package saves about $160B on drug prices Bloomberg Insurers Balk at Paying for Biogen’s $56,000-a-Year Alzheimer’s Treatment Chemical & Engineering News Avilar Therapeutics launches with $60 million to degrade extracellular targets Reuters Wait what? FDA wants 55 years to process FOIA request over vaccine data Bloomberg Novartis Has a Big Pile of Cash and Investors Wanting Action Reuters J&J sees potential for 14 new multibillion-dollar drugs by 2025 Suggest a story we should read Upcoming Event Getting Your Data Aggregation Contract Right in Pharma Dec. 2, 2021 - Dec. 2, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip